Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Discharge 50% Improvement Relative Risk HCQ for COVID-19  Li et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 28 patients in China Higher discharge with HCQ (not stat. sig., p=0.086) c19hcq.org Li et al., Science China Life Sciences, Jan 2021 Favors HCQ Favors control

Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19

Li et al., Science China Life Sciences, doi:10.1007/s11427-020-1871-4
Jan 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Small RCT comparing HCQ and CQ in China with 88 very late stage (17.6 days from onset to hospitalization and ~10 days to randomization) patients. The primary clinical outcomes (TTCR and TTCI) were not significantly different. Authors note that HCQ may have more promising efficacy in immune system modulation, indicated by ferritin reduction in the moderate cases and improvement of CT scores and lymphocyte counts in the severe cases. HCQ and CQ were well tolerated.
Authors also compare RCT patients to a matched sample of non-RCT patients in the same hospital, showing shorter time to discharge with CQ/HCQ, but not statistically significant due to the small size.
risk of no hospital discharge, 50.0% lower, HR 0.50, p = 0.09, treatment 14, control 14, RCT patients vs. matched sample of non-treated patients.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Li et al., 18 Jan 2021, retrospective, China, peer-reviewed, 21 authors.
This PaperHCQAll
Abstract: SCIENCE CHINA Life Sciences •LETTER TO THE EDITOR• April 2021 Vol.64 No.4: 660–663 https://doi.org/10.1007/s11427-020-1871-4 Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19 1† 2† 3† 4 5 6 7 Qiuyu Li , Cheng Cui , Fei Xu , Jianping Zhao , Nan Li , Haichao Li , Tianbing Wang , 5 2,8 2 2 2 8 2 Hua Zhang , Na Liu , Yudong Wei , Xiaoye Niu , Yan Xu , Jianping Dong , Xueting Yao , 1 1 2,9 10 10 2* Xiaohong Wang , Yahong Chen , Haiyan Li , Chunli Song , Jie Qiao , Dongyang Liu & 1* Ning Shen 1 Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing 100191, China; 2 Drug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China; 3 Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China; 4 Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China; 5 Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing 100191, China; 6 Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing 100034, China; 7 Trauma Center, Peking University People’s Hospital, Beijing 100044, China; 8 Beijing Haidian Hospital, Haidian Section of Peking University Third Hospital, Beijing 100080, China; 9 Department of Cardiology, Peking University Third Hospital, Beijing 100191, China; 10 Institute of Medical Innovation, Peking University Third Hospital, Beijing 100191, China Received August 19, 2020; accepted December 18, 2020; published online January 18, 2021 Citation: Li, Q., Cui, C., Xu, F., Zhao, J., Li, N., Li, H., Wang, T., Zhang, H., Liu, N., Wei, Y., et al. (2021). Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19. Sci China Life Sci 64, 660–663. https://doi.org/ 10.1007/s11427-020-1871-4 Dear Editor, Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been rapidly spreading worldwide. Hydroxychloroquine and chloroquine are candidates for the treatment of coronavirus disease 2019 (COVID-19) owing to its antiviral effect and immunomodulation properties. However, the published results of utilizing hydroxychloroquine and chloroquine as treatment were still controversial and their efficacy and safety in patients with COVID-19 need to be further elucidated. A total of 88 laboratory-confirmed (identified by viral †Contributed equally to this work *Corresponding authors (Ning Shen, email: shenning1972@126.com; Dongyang Liu, email: liudongyang@vip.sina.com) RNA or antibody tests) patients with COVID-19 (65 moderate and 23 severe patients with COVID-19) were included in our multicenter, randomized controlled trial (RCT). Eligible patients randomly assigned in a 1:1 ratio to orally receive hydroxychloroquine (600 mg twice a day on the first day followed by 200 mg twice a day in the last four days) plus standard care or chloroquine (500 mg twice a day for the first three days followed by 250 mg twice a day in the last two days) plus standard care (SC) for 5 days. Our study protocol is provided in the Supplementary Methods. The average age of our patients was 61.3 years old and they had a higher risk of developing severe illness. The average time interval..
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit